Armaturenbau

Bernd Armaturenbau Spezialanfertigungen Industriearmaturen Schlauchverbinder Rohrverschraubungen

Eintrag vom: 19.06.2013.

"Results from the LEVEL UP study highlight how treatment options such as upadacitinib can achieve high treatment goals in atopic dermatitis with combined measures of EASI 90 and NRS 0/1 not just itch resolution or just skin clearance."

 

New and Deepening of Response Over Time: A meaningful proportion of patients achieved new EASI -75 EASI -90 Itch NRS and vIGA-AD 0/1 responses at Week 52 supporting increased disease control with prolonged therapy and less frequent dosing.

 

Eczema Area and Severity Index-90 (EASI-90) Responder Rates With Abrocitinib and Relationship With Quality of Life (QoL) and Itch in Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From a Randomized Phase 3 Clinical Trial

 

We chose to evaluate EASI 90 and PP-NRS 0/1 since they are the most common endpoints in clinical trials. At weeks 16 24 and 52 30.1% 39.3% and 56.5% of our patients respectively achieved EASI 90 and PP-NRS of 0/1 simultaneously reaching an optimal disease control.

 

Upadacitinib demonstrated superior efficacy compared to dupilumab in the primary end point of the simultaneous achievement of a 90% or greater reduction in Eczema Area and Severity Index (EASI-90) and a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at week 16.

 

Very low disease activity?defined as EASI-90 plus I-NRS 0/1?was achieved in 20.6% of mid-dose patients versus 4.5% on placebo (p<0.01 for both); the company characterized this composite outcome as not previously reported with any biologic.

 

At week 2 a greater proportion of patients treated with upadacitinib vs placebo and vs dupilumab simultaneously achieved EASI 90 and WP-NRS 0/1 as well as EASI ? 3 and WP-NRS 0/1.

 

View RINVOQ® (upadacitinib) efficacy for the treatment of refractory moderate to severe Atopic Dermatitis (AD) including EASI 75 and EASI 90 data before and after photos and itch data.